JOURNAL OF NEURAL TRANSMISSION神经传递杂志
JOURNAL OF NEURAL TRANSMISSION(英文缩写 J NEURAL TRANSM),ISSN 0300-9564,eISSN 1435-1463,中文译名:神经传递杂志 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-27 至 2026-09-27，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 3.850 | Q2 |
| 2022 | 3.300 | Q2 |
| 2023 | 3.200 | Q2 |
| 2024 | 4.000 | Q1 |
| 2025 | 4.400 | Q1 |
JOURNAL OF NEURAL TRANSMISSION 最新收录文献
-
1. Concomitant pathologies and their impact on schizophrenia: a narrative overview of current evidence.
PMID:日期:2026-09-24Schizophrenia is a complex, heterogeneous, and disabling psychiatric disorder that disrupts cognitive, perceptual, and emotional functioning. In over 70% of patients, it is associated with multiple psychiatric and somatic comorbidities that, together with lifestyle and substance abuse, contribute to lower quality of life and reduced life expectancy. Other major psychiatric comorbidities, such as anxiety, depression, and bipolar disorder, often show considerable overlap with schizophrenic symptoms and are difficult to differentiate. The substrate of dementia in older schizophrenics and co-existing Alzheimer disease is a matter of discussion. Other common comorbidities like obsessive-compulsive and personality disorders predominate, while prenatal risk factors such as dysmorphologies, hypoxia, and infections may occur premorbidly or at illness onset. Among somatic comorbidities, cardiovascular and cerebrovascular diseases, metabolic syndrome, and diabetes are most frequent and show some genetic overlap with schizophrenia. Clinical and research interests in the co-occurring issues of schizophrenia are caused by the presence of multiple coexisting psychopathologies as well as comorbid medical conditions that may increase mortality. Current evidence suggests involvement of multiple neurotransmitter systems (dopaminergic, glutamatergic, and GABAergic), prefrontal cortical involvement, and corticostriate-thalamo-cortical circuit dysfunctions in the pathogenesis of both schizophrenia and many key psychiatric comorbidities, while the evidence implicating biological pathways affecting both body and brain is increasing for most somatic comorbidities. Although environmental bias increases throughout the disease course, the pathogenic factors for the majority of concurrent pathologies and their clinical implications warrant further attention.
-
2. Stress and Parkinson's disease: from dysfunctional detection to impaired handling: a narrative review.
PMID:日期:2026-09-24Stress can precipitate Parkinson's disease (PD), and conversely, PD imposes substantial stress on affected individuals. Controlled studies support this bidirectional relationship. Recent observations during the Covid‑19 pandemic suggested that PD patients may sometimes display an unexpected resilience to stressful events (SE), in particular in terms of missing motor deterioration. However, this "favorable" interpretation can be misleading as PD is characterized by dysfunctional stress detection and stress processing. Furthermore, reduced stress‑related cardiac morbidity has not been demonstrated uncontestably. Indeed, detailed analyses indicate that involvement of non‑dopaminergic systems modifies-rather than mitigates-stress responses. Lewy body pathology already compromises activation of the hypothalamic-pituitary-adrenal (HPA) axis, while autonomic cardiac responses are blunted. Dysfunction of the superior colliculi impairs instant detection of stress events (SE); degeneration of the pedunculopontine nucleus disrupts appropriate motivational appraisal of the SE. Impaired contrast discrimination and olfaction hinder immediate perceptual SE assessment. Locus coeruleus involvement reduces alertness, further limiting SE evaluation. Finally, at the nexus of stress handling, dysfunctional amygdalar networks contribute to diminished autonomic reactivity and altered emotional processing. This review synthesizes current knowledge on peripheral and central stress‑related systems affected by PD pathophysiology. It outlines established, emerging, and theoretical therapeutic strategies, including approaches informed by the Stress Reduction Theory and the Attention Restoration Theory. It underscores the need for systematic investigation into stress mechanisms in PD, an area that remains insufficiently explored.
-
3. On-demand therapies-emergency medication or daily routine?
PMID:日期:2026-09-24Fluctuations represent a major therapeutic challenge in Parkinson's disease (PD) and become increasingly prevalent with disease progression. While oral and device-aided therapies (DAT) improve symptom control, patients continue to experience disabling OFF episodes, in particular early morning OFFs, delayed ON, and no-ON phenomena. Increasing evidence suggests that both motor and non-motor fluctuations are more common than previously recognized and contribute substantially to impaired quality of life. Fluctuations affect up to 50% of patients within five years of disease onset to eventually affect almost all patients with longer duration. Beside altered central pharmacodynamics, peripheral mechanisms such as dysphagia, gastroparesis, altered intestinal absorption, and microbiome-mediated levodopa degradation, contribute to fluctuations. Although oral adjunct medication and DAT reduce daily OFF-time, clinically meaningful OFF periods often persist. This is where on-demand therapies provide rapid symptom relief and address the limitations of conventional oral medication and DAT. Hence, more regular, even daily use of on-demand therapies may improve quality of life in patients with PD. However, the potential impact of on-demand therapies on non-motor OFF periods needs further investigation. Side effects, handling and economic considerations should be taken into account. This expert perspective concludes that given the high prevalence and clinical relevance of fluctuations, on-demand therapies may be considered as an integral component of standard PD management rather than solely as a rescue option in rare emergency situations. Implementation may be particularly beneficial for patients experiencing early-morning-OFFs, delayed and no-ONs but also predictable and unpredictable OFFs.
-
4. Pain characteristics in isolated cervical dystonia: comparison to orthopedic cervical conditions and assessment of botulinum toxin effects.
PMID:日期:2026-09-24The objective was to characterize pain and evaluate quality of life (QoL) in cervical dystonia (CD) by comparing pain profiles with patients affected by orthopedic cervical conditions (OCC) and evaluating differences between CD patients with and without head tremor (HT). Additionally, longitudinal changes after botulinum toxin (BoNT) treatment in CD were assessed. Pain is the most prevalent non-motor symptom in CD. However, its clinical characteristics and underlying mechanisms are incompletely understood. Isolated CD and OCC patients were evaluated regarding pain characteristics and QoL using self-report questionnaires. CD patients additionally underwent blinded motor assessment and were stratified according to the presence of HT. A subset of CD patients was reevaluated 4-6 weeks after BoNT treatment. 49 CD patients and 49 OCC patients were investigated. The overall pain profile was comparable between CD and OCC; only nociceptive pain perception was higher in OCC than in CD. HT in CD patients was associated with increased nociceptive pain and greater QoL impairment. Following BoNT injection in CD, pain and QoL improved significantly. The marked similarities of pain profiles in CD and OCC together with the increased nociceptive pain in CD patients with HT suggest that musculoskeletal mechanisms contribute to pain in CD. Improvement of pain and QoL in CD patients with long disease duration after BoNT treatment indicates the relevant effect on non-motor symptoms. Further studies are needed to clarify the underlying pathophysiology of pain in CD.
-
5. Access, stigma and community engagement: implementation strategies for rural and underserved populations.
PMID:日期:2026-09-24Parkinson's disease remains one of the fastest growing neurodegenerative disorder. Optimal care for the patients may include proper medication dispensation and adjustment, physiotherapy, speech and swallowing therapy, and in some cases advanced device-aided therapy. These may incur a high cost and rendered unaffordable, especially in lower socioeconomic countries where government subsidies maybe limited. Moreover, gaining access to care may be difficult and expensive, especially among those in rural areas. Additionally, cultural contexts may delay care-seeking, especially in Asia where the concept of "face" plays a prominent role in society. Here, we briefly review the current status of access to care in Asia, stigma in the context of Asian patients, and how community engagement can help reduce the barriers to care of people with Parkinson's. We provide various ways to engage the community, their barriers and how they could be overcome, and two real-life examples of community engagement done in India and Thailand to reduce the gap in care, stigma and increase public awareness of Parkinson's.
-
6. Altered iron metabolism and iron therapy in restless legs syndrome.
PMID:日期:2026-09-24Restless legs syndrome (RLS) is a common neurological disorder that impairs sleep and reduces quality of life. The pathogenesis of RLS is incompletely understood. However, two mechanisms in its pathogenesis have been well accepted: iron deficiency, particularly brain iron deficiency, and subsequent dopamine dysregulation, which contribute to sensorimotor symptoms in RLS. In this review, we aim to provide a balanced synthesis of the literature on peripheral and brain iron dysregulation and iron therapy in RLS. We conclude that brain iron deficiency is central to the pathogenesis of RLS, whereas peripheral iron deficiency, although closely linked to RLS, poorly reflects brain iron status. Brain iron deficiency in RLS likely arises from altered iron metabolism at multiple levels, including impaired iron transport at the blood-brain interface and in subcortical neuronal structures such as the dopaminergic and thalamic systems, and potentially altered iron export, with or without systemic iron deficiency. These processes are further modulated by circadian-related changes, genetic susceptibility, and sex differences, adding complexity to iron dysregulation in RLS. Iron therapy, both oral and IV formulations, has become a standard of care in the treatment of RLS. Further research is needed to deepen our understanding of brain iron deficiency, improve the prediction of treatment response, and optimize the selection of iron therapies for RLS.
-
7. Weight changes and physical activity in Parkinson's disease: converging markers of energy balance, disease progression, and lifestyle-based care.
PMID:日期:2026-09-24Weight changes are common but often overlooked in Parkinson's disease (PD), occurring across prodromal, early, and advanced disease stages. Weight loss may reflect increased energy expenditure, dysautonomia, dysphagia, gastrointestinal dysfunction, altered appetite, and involvement of central pathways regulating hunger, satiety, and reward. Conversely, weight gain may occur in relation to dopaminergic treatment, impulse-control or binge-eating behaviours, reduced mobility, and post-surgical changes. Emerging longitudinal data suggest that weight variability is not merely a nutritional issue, but may identify distinct clinical trajectories, including faster cognitive and functional decline in patients with weight loss and different motor/non-motor patterns in those with weight gain. In parallel, physical activity and structured exercise are increasingly recognized as central components of PD care, with evidence supporting symptomatic benefits, possible disease-modifying effects, and even a protective association against incident PD. This review examines the intersection between weight changes and physical activity in PD, proposing that both reflect a broader disruption of energy balance, motor reserve, metabolic regulation, and lifestyle-related resilience. We discuss clinical mechanisms, biomarkers, prognostic implications, and practical approaches to integrate weight monitoring, nutritional assessment, and individualized physical activity prescriptions into routine PD care.
-
8. GNAL-associated dystonia: clinical spectrum, genetic features, and genotype-phenotype correlations.
PMID:日期:2026-09-24Despite increasing recognition of GNAL-associated dystonia as a genetic cause of adult-onset isolated cervical dystonia, the full phenotypic spectrum, longitudinal pattern of disease progression, and genotype-phenotype relationships remain incompletely defined. We retrospectively reviewed our case of genetically confirmed patient with GNAL-associated dystonia and reviewed genetically confirmed cases published up to June 2026. Demographic, clinical, treatment, neuroimaging, and genetic data were extracted. Genotype-phenotype comparisons were performed between patients with missense and loss-of-function (LoF) variants. Our review showed seventy-six patients, with a median age at onset of 35 years (IQR, 22-44) and female predominance (57.9%). Dystonia was predominantly focal at onset, with cervical dystonia being most common; and 54% patients with focal onset progressed to segmental or generalized dystonia, with a median time to generalization of 6 years. Most patients had isolated dystonia. Among 46 detected genetic variants, missense variants predominated and nearly all were heterozygous. Twelve patients underwent globus pallidus interna deep brain stimulation (GPi-DBS), with greatest benefit for cervical dystonia. The LoF variants were associated with a shorter time to generalization than missense variants (2 vs. 10 years, p=0.021). This association was not confirmed in a censoring-based survival analysis (log-rank p=0.904) and should be regarded as hypothesis-generating. GNAL-associated dystonia presents as adult-onset isolated dystonia with focal onset, with substantial longitudinal progression to segmental or generalized dystonia (54%). GPi-DBS appears beneficial, particularly for cervical dystonia. The genetic spectrum is highly heterogeneous, with predominantly heterozygous missense distributed across the α-helical and Ras-like GTPase domains. The observed association between LoF variants and more rapid generalization warrants validation in larger longitudinal cohorts.
-
9. Early clinical experience with IPX203 in Parkinson's disease with motor fluctuations.
PMID:日期:2026-09-22Motor fluctuations remain a major challenge in the treatment of Parkinson's disease (PD). IPX203 is a novel extended-release formulation of levodopa/carbidopa designed to provide rapid onset of benefit while maintaining therapeutic levodopa concentrations for a longer duration than immediate-release formulations. This review summarizes the formulation, pharmacokinetic profile, and clinical efficacy of IPX203 and discusses early clinical experience following its introduction into routine practice in the United States. Phase 2 studies demonstrated rapid levodopa absorption and prolonged plasma exposure, while the phase 3 RISE-PD trial showed significantly greater Good ON time with fewer daily doses compared with optimized immediate-release levodopa/carbidopa. The unique formulation combines immediate-release granules with mucoadhesive extended-release pellets that prolong levodopa delivery within the proximal small intestine. Early clinical experience suggests that many patients achieve meaningful improvements in motor fluctuations, treatment convenience, and overnight symptom control following conversion to IPX203. Three representative patient vignettes illustrate common clinical scenarios and practical approaches to treatment optimization. IPX203 provides a novel oral levodopa/carbidopa delivery strategy that combines rapid onset with prolonged duration of benefit. Clinical trial data and early clinical experience support its use as an effective option for patients with PD experiencing motor fluctuations and highlight the importance of individualized treatment optimization to maximize therapeutic benefit.
-
10. Single ayahuasca administration mitigates long-term behavioral and neurochemical effects of early-life stress in rats.
PMID:日期:2026-09-19Pharmacotherapy for depression is commonly prescribed, yet fewer than half of patients achieve remission with a single treatment. Many also experience intolerable side effects, highlighting the need for new treatment approaches. Classic psychedelics interact with the serotonin (5-HT) receptor class and are therefore strongly involved in the treatment of psychiatric illnesses such as depression, anxiety, and substance abuse, demonstrating great therapeutic potential. Specifically, Ayahuasca (AYA) is primarily used for physical or spiritual healing, and the effects resulting from its use are related to its serotonergic activation. Thus, the present study aimed to evaluate the behavioral and neurochemical effects of ayahuasca treatment in Wistar rats subjected to an animal model of depression induced by maternal deprivation (MD). To induce depressive-like behavior, MD was performed on the pups for 3 h/day for 10 days (1st to 10th day of life). Subsequently, rats underwent behavioral testing to assess anxiety- and depressive-like behavior using the elevated plus maze, open field test, splash test, and forced swim test. The levels of dopamine (DA), serotonin (5-HT), brain-derived neurotrophic factor (BDNF), antioxidant enzymes superoxide dismutase, catalase, glutathione peroxidase, and glutathione reductase activities, and oxidative stress biomarkers were assessed in the frontal cortex, hippocampus, and striatum 15 days after ayahuasca administration. MD promoted increased anxiety-like and depressive-like behaviors. Also, anxiety-like and depressive-like behaviors, as well as decreased BDNF and monoamine levels and increased oxidative stress induced by this model, were attenuated by treatment with a single dose of AYA, demonstrating significant therapeutic potential. The findings highlight the need for translational research of new pharmacological approaches for MDD.